Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Cali Biosciences（加立生物科技有限公司）is an international biopharmaceutical company primarily engaged in the R&D and future commercialization of innovative drugs. According to its official website, the company focuses on perioperative medications, covering areas such as anesthesia, analgesia, and anti-inflammation. It has offices and laboratories in Shenzhen, a clinical center in Shanghai, and operating entities in San Diego, USA, and Hong Kong.
The website is not centered on online medical services, but rather on showcasing the company’s R&D capabilities and pipeline. Its key focus areas include a perioperative drug development pipeline, multiple drug candidates, complex injectables, proprietary drug delivery technology platforms, and the development of improved new drugs under the 505(b)(2) regulatory pathway. The news section discloses progress such as a strategic partnership with Grand Life Sciences, publication of Phase 2 study results, and the launch of Phase III studies, indicating that the company has a relatively clear clinical development roadmap.
The official website does not provide any pricing information for consumers or institutional clients, nor does it list drug procurement prices, licensing fees, or partnership quotations. For this type of biopharmaceutical company, value is mainly reflected in its R&D pipeline, clinical data, patent barriers, regulatory approvals, and commercialization partnerships, rather than standardized online subscriptions or software fees.
The advantages are its focused therapeutic area: perioperative anesthesia, analgesia, and anti-inflammatory needs are clearly defined, and the company emphasizes its proprietary delivery technologies and international team. Its stated regulatory submission goals in China, the U.S., and Europe also reflect ambitions for the global market. The downside is that the website’s disclosures remain relatively high-level, with limited information on specific drug candidate mechanisms, clinical endpoints, trial sizes, competitive landscape, and commercialization timelines. For investors, partners, or physicians seeking deeper evaluation, it would still be necessary to consult clinical trial registries, papers, announcements, and regulatory filings.
This website is suitable for pharmaceutical industry professionals, researchers in hospital anesthesia and perioperative care, CRO and commercialization partners, investment institutions, and people interested in innovative drug development. For ordinary patients looking to purchase medicines or find treatment options, the official website is currently not a direct service portal.
The domain is the company’s official website, and the company is headquartered in Shenzhen, China. Based on currently available information, it should be directly accessible from mainland China. Overall, the site functions more as a corporate showcase, with relatively few interactive features and a low access barrier.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on calibiosciences.com official site.
calibiosciences.com is an China Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach calibiosciences.com directly.